The American Society of Clinical Oncology has made public its detailed guidance to CMS, supporting implementation of physician-focused and other alternative payment models under MACRA.
When President Obama signed legislation authorizing the Medicare Access and CHIP Reauthorization Act or MACRA to replace the much-despised sustainable growth rate formula, commonly known as SGR, on April 16, 2015, a big sigh of relief could be heard from providers. Praising the lawmakers who worked toward avoiding the 21% reimbursement cut under SGR—since the formula was linked to the gross domestic product—Obama said, “This bill is consistent with that proposal — it’s a milestone for physicians, and for the seniors and people with disabilities who rely on Medicare for their health care needs.”
In response to CMS’ request for information, the American Society of Clinical Oncology (ASCO) has made public its detailed guidance to the federal body, supporting implementation of physician-focused and other alternative payment models (APMs) under MACRA.
In a press release summarizing the guiding principles developed by ASCO, the organization’s President Julie Vose, MD, MBA, FASCO, said, “As CMS works to transform the Medicare physician reimbursement system, we provided—and will continue to provide—the agency with robust feedback based on what we've learned over many years from ASCO's payment reform efforts.”
The following are the 11 guiding principles provided by ASCO to CMS that would ensure a sustainable Medicare payment system in clinical oncology:
Vose is the keynote speaker at The American Journal of Managed Care’s Patient-Centered Oncology Care 2015 meeting in Baltimore, being held November 19-20, 2015.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More